Cerebrolysin dosage: reported doses and schedule
An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Also called: FPF-1070, Cerebrolysin concentrate.
Nootropic peptides · Porcine brain-derived peptide and amino-acid mixture · Evidence: Approved drug.
Typical reported dose: 30 mL by IV drip once a day for at least 10 days
- CASTA: 30 mL: 30 mL once daily once daily, into a vein. Studied in a trial. Studied in: Ischemic stroke within 12 hours. (source)
- Alteplase trial: 30 mL: 30 mL once daily once daily, into a vein. Studied in a trial. Studied in: Ischemic stroke receiving alteplase within 3 hours. (source)
- Stroke trial: 50 mL: 50 mL once daily once daily, into a vein. Studied in a trial. Studied in: Acute stroke within 24 hours. (source)
- CARS: 30 mL with rehabilitation: 30 mL once daily once daily, into a vein. Studied in a trial. Studied in: Stroke rehabilitation starting 24–72 hours after onset. (source)
- Subacute stroke: 30 mL: 30 mL once daily once daily, into a vein. Studied in a trial. Studied in: Motor impairment; treatment on stroke days 8–28. (source)
- Extended rehabilitation: 30 mL: 30 mL once daily once daily, into a vein. Studied in a trial. Studied in: Severe arm impairment around 10 days after stroke. (source)
Highest studied: 10 mL/day IM is the highest verified human exposure located, in a small retrospective cohort..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Cerebrolysin
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- PE-22-28: An experimental mood peptide studied in mice, with no human trials found.
- Dihexa: An experimental memory compound with disputed animal research and no established human dose.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke., Beghi E et al. · European journal of neurology · 2021
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- CEREBROLYSIN, BASG
- Drug Product Database online query, Health Canada
- PHARMACY & POISONS BOARD OF HONG KONG | 香港藥劑業及毒藥管理局, Hong Kong Department of Health
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.